Abbott Laboratories

ABT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $44.33B $41.95B $40.11B $43.65B $43.08B $34.61B $31.90B $30.58B
Established Pharmaceutical Products $5.54B $5.19B $5.07B $4.91B $4.72B $4.30B $4.49B $4.42B
Nutritional Products $8.45B $8.41B $8.15B $7.46B $8.29B $7.65B $7.41B $7.23B
Diagnostic Products $8.94B $9.34B $9.99B $16.58B $15.64B $10.81B $7.71B $7.50B
Vascular Products
Medical Devices $21.39B $18.99B $16.89B $14.69B $14.37B $11.79B $12.24B $11.37B
Other $17.0M $16.0M $14.0M $11.0M $52.0M $66.0M $57.0M $62.0M
Cost of Revenue $19.32B $18.71B $17.98B $19.14B $18.54B $15.00B $13.23B $12.71B
Gross Profit $25.01B $23.24B $22.13B $24.51B $24.54B $19.61B $18.67B $17.87B
Gross Margin 56.4% 55.4% 55.2% 56.1% 57.0% 56.6% 58.5% 58.4%
Operating Expenses
Research & Development $2.94B $2.84B $2.74B $2.89B $2.74B $2.42B $2.44B $2.30B
SG&A Expense $12.33B $11.70B $10.95B $11.25B $11.32B $9.70B $9.77B $9.74B
Operating Income $8.05B $6.83B $6.48B $8.36B $8.43B $5.36B $4.53B $3.65B
Operating Margin 18.2% 16.3% 16.2% 19.2% 19.6% 15.5% 14.2% 11.9%
Interest Expense $637.0M $558.0M $533.0M $546.0M $670.0M $826.0M
Pretax Income $8.47B $7.01B $6.66B $8.31B $8.21B $4.97B $4.08B $2.87B
Income Tax Expense $1.94B $-6.39B $941.0M $1.37B $1.14B $497.0M $390.0M $539.0M
Net Income $6.52B $13.40B $5.72B $6.93B $7.07B $4.50B $3.69B $2.37B
Net Margin 14.7% 31.9% 14.3% 15.9% 16.4% 13.0% 11.6% 7.7%
EPS (Basic) $3.73 $7.67 $3.28 $3.94 $3.97 $2.52 $2.07 $1.34
EPS (Diluted) $3.72 $7.64 $3.26 $3.91 $3.94 $2.50 $2.06 $1.33
Shares Outstanding (Basic) 1.74B 1.74B 1.74B 1.75B 1.78B 1.77B 1.77B 1.76B
Shares Outstanding (Diluted) 1.75B 1.75B 1.75B 1.76B 1.79B 1.79B 1.78B 1.77B
Dividends Per Share $2.40 $2.24 $2.08 $1.92
← Newer Page 1 of 3 Older →